Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-148-4 | CAS number: 25637-99-4
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
HBCDD did not induce sensitisation in a mouse local lymph node assay or in a guinea pig maximisation study. Both studies were conducted according to international guidelines and GLP using a composite of commercial products from three manufacturers (i.e. Albemarle, Chemtura and ICL-IP). Earlier studies performed in Japan using a test substance of unknown composition reported positive results. These studies were not conducted according to GLP nor current guidelines. For the test substance provided by Albemarle, Chemtura and ICL-IP it can be concluded that HBCDD does not have skin sensitising potential. This was also concluded in the EU Risk Assessment Report (EC, 2008).
Migrated from Short description of key information:
The following information is available for this endpoint:
Guinea pig maximisation: Wenk, M. L. (1996). Maximisation test in Guinea Pigs. Report no.: M96AO61.1X64. Report date: 1996-11-08.
Mouse local lymph node assay: Woolhiser, M. R. and Anderson, P. K. (2003). Hexabromocyclododecane: Contact sensitisation potential via the local lymph node assay (including a primary irritancy screen) using CBA/J mice. Report no.: 031013. Report date: 2003-07-14.
Respiratory sensitisation
Endpoint conclusion
- Additional information:
No information was available for respiratory sensitisation. As HBCDD is not a skin sensitiser and no cases of respiratory sensitisation have been reported in the literature, the substance is unlikely to have respiratory sensitisation potential.
Migrated from Short description of key information:
No information was available for respiratory sensitisation. As the substance is not skin sensitising and no cases of respiratory sensitisation have been reported in the literature, HBCDD is unlikely to have a respiratory sensitisation potential.
Justification for classification or non-classification
Based upon the results of the key study (Woolhiser and Anderson, 2003), HBCDD does not meet the criteria for classification according to 67/548/EEC and EC Regulation 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
